Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday, Zacks.com reports.

According to Zacks, “Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s lead program, SIRPaFc (TTI-621), is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (do not eat) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (eat) signals. A Phase 1 clinical trial (NCT02663518) evaluating SIRPaFc is ongoing. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. “

Separately, HC Wainwright lowered their price objective on Trillium Therapeutics from $10.00 to $4.00 and set a “buy” rating for the company in a research report on Wednesday, March 13th.

NASDAQ:TRIL traded up $0.01 during mid-day trading on Wednesday, reaching $0.59. The stock had a trading volume of 1,900 shares, compared to its average volume of 876,830. The company has a market capitalization of $12.39 million, a price-to-earnings ratio of -0.25 and a beta of 2.22. Trillium Therapeutics has a one year low of $0.51 and a one year high of $7.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.56 and a quick ratio of 3.56.

Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) last released its earnings results on Monday, March 11th. The biotechnology company reported ($0.42) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.66) by $0.24. As a group, sell-side analysts anticipate that Trillium Therapeutics will post -1.93 EPS for the current year.

Hedge funds have recently made changes to their positions in the business. Two Sigma Investments LP purchased a new position in shares of Trillium Therapeutics during the fourth quarter valued at approximately $35,000. Jane Street Group LLC purchased a new position in shares of Trillium Therapeutics during the fourth quarter valued at approximately $43,000. Geode Capital Management LLC increased its stake in shares of Trillium Therapeutics by 164.0% during the fourth quarter. Geode Capital Management LLC now owns 26,627 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 16,541 shares during the period. Oxford Asset Management LLP increased its stake in shares of Trillium Therapeutics by 64.0% during the first quarter. Oxford Asset Management LLP now owns 93,589 shares of the biotechnology company’s stock valued at $62,000 after buying an additional 36,534 shares during the period. Finally, Marshall Wace LLP purchased a new position in shares of Trillium Therapeutics during the first quarter valued at approximately $73,000. Hedge funds and other institutional investors own 27.22% of the company’s stock.

Trillium Therapeutics Company Profile

Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides.

Further Reading: Return on Equity (ROE)

Get a free copy of the Zacks research report on Trillium Therapeutics (TRIL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.